3 enrolling by invitation. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 3 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of Vormatrigine in Adult Patients With Epilepsy vormatrogine - Epilepsy, Tonic-Clonic, Focal Seizure | Phase 3 | Enrolling by invitation | Praxis Precision Medicines | 700 | 2025-10-27 | 2026-08-03 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) LP352 - Developmental and Epileptic Encephalopathy | Phase 3 | Enrolling by invitation | Longboard Pharmaceuticals | 324 | 2025-02-12 | 2026-10-14 |
| An Open-label Study of XEN1101 in Epilepsy XEN1101 - Focal Epilepsy, Tonic-Clonic Seizures | Phase 3 | Enrolling by invitation | Xenon Pharmaceuticals Inc. | 880 | 2023-04-25 | 2026-11-02 |
Seizures (3) · Epilepsies, Myoclonic (1) · Epilepsies, Partial (1) · Epilepsy, Tonic-Clonic (1) · Lennox Gastaut Syndrome (1) · Neurodevelopmental Disorders (1)
Brain Diseases (3) · Central Nervous System Diseases (3) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Epilepsy, Generalized (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Epileptic Syndromes (1) · Genetic Diseases, Inborn (1) · Mental Disorders (1)
XEN1101 (1)
Longboard Pharmaceuticals (1) · Praxis Precision Medicines (1) · Xenon Pharmaceuticals Inc. (1)
Germany (3) · Italy (3) · Spain (3) · United States (3) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · France (2) · Mexico (2) · Netherlands (2) · Poland (2) · Portugal (2) · United Kingdom (2) · Argentina (1)